Additionally, the 36-month beta value for GH is 1.41. There are mixed opinions on the stock, with 15 analysts rating it as a “buy,” 7 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for GH is 117.69M and currently, short sellers hold a 7.54% ratio of that float. The average trading volume of GH on June 26, 2025 was 2.21M shares.
GH) stock’s latest price update
The stock price of Guardant Health Inc (NASDAQ: GH) has plunged by -0.18 when compared to previous closing price of 49.99, but the company has seen a 0.75% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-23 that GH gains ground with stronger guidance, improving margin and Reveal’s breakout as TEM scales fast but stays unprofitable.
GH’s Market Performance
GH’s stock has risen by 0.75% in the past week, with a monthly rise of 31.32% and a quarterly rise of 7.40%. The volatility ratio for the week is 2.44% while the volatility levels for the last 30 days are 2.78% for Guardant Health Inc The simple moving average for the past 20 days is 5.79% for GH’s stock, with a 34.53% simple moving average for the past 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Mizuho repeating the rating for GH by listing it as a “Outperform.” The predicted price for GH in the upcoming period, according to Mizuho is $55 based on the research report published on April 10, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see GH reach a price target of $60. The rating they have provided for GH stocks is “Overweight” according to the report published on January 23rd, 2025.
Guggenheim gave a rating of “Buy” to GH, setting the target price at $36 in the report published on June 28th of the previous year.
GH Trading at 11.52% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.71% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Tariq Musa, who sale 3,213 shares at the price of $49.47 back on Jun 18 ’25. After this action, Tariq Musa now owns 7,190 shares of Guardant Health Inc, valued at $158,947 using the latest closing price.
POTTER MYRTLE S, the Director of Guardant Health Inc, sale 26 shares at $49.47 during a trade that took place back on Jun 18 ’25, which means that POTTER MYRTLE S is holding 18,154 shares at $1,286 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.59 for the present operating margin
- 0.61 for the gross margin
The net margin for Guardant Health Inc stands at -0.54. The total capital return value is set at -0.41. Equity return is now at value -4584.47, with -27.33 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -5.21. The interest coverage ratio of the stock is -166.83.
Currently, EBITDA for the company is -390.12 million with net debt to EBITDA at -1.53. When we switch over and look at the enterprise to sales, we see a ratio of 8.77. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
In conclusion, Guardant Health Inc (GH) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
